News & Updates

Show Multimedia Only

Tebentafusp delivers 5-year survival benefit in metastatic uveal melanoma

08 Sep 2026 by

Long-term survival benefits with tebentafusp persist in previously untreated HLA-A∗02:01-positive patients with unresectable or metastatic uveal melanoma (mUM), as shown in the longest survival follow-up of a phase III trial.

Tebentafusp delivers 5-year survival benefit in metastatic uveal melanoma

08 Sep 2026

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

03 Sep 2026 by

A five-infusion course of veligrotug, a full antagonist monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), over 12 weeks results in improved diplopia, proptosis, and disease activity and is well tolerated in patients with active thyroid eye disease (TED), as shown in the phase III THRIVE study. Moreover, the therapeutic effect persists through week 52.

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

03 Sep 2026

NSAID use lowers risk of developing AMD

02 Sep 2026

Patients prescribed NSAIDs appear protected against the development of age-related macular degeneration (AMD) compared with nonusers, suggests a study.

NSAID use lowers risk of developing AMD

02 Sep 2026

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

Smart eyeglasses show mixed results in feasibility study

25 Aug 2026 by

Artificial intelligence (AI)-powered smart eyeglasses, used as an assistive tool for individuals with low vision or blindness, work well for identifying common objects but fall short in tasks involving colours and coin money, as shown in a pilot feasibility study.

Smart eyeglasses show mixed results in feasibility study

25 Aug 2026

Dexamethasone eye drops show promise in type 1 retinopathy of prematurity

12 Aug 2026

Treatment with dexamethasone eye drops is safe and may reduce the need for invasive treatment in preemies with type 1 retinopathy of prematurity (ROP), according to the DROPROP study.

Dexamethasone eye drops show promise in type 1 retinopathy of prematurity

12 Aug 2026

Prosthetic capsular bag shows potential in scleral fixation of IOL in eyes with no capsular support

06 Aug 2026

Researchers have developed a prosthetic capsular bag (PCB) for posterior scleral fixation of an intraocular lens (IOL) in eyes without capsular support, with a recent study demonstrating its viability.

Prosthetic capsular bag shows potential in scleral fixation of IOL in eyes with no capsular support

06 Aug 2026

Older age, ocular hypertension predict glaucoma in eyes with PXF syndrome

06 Aug 2026

Perimetric glaucoma may develop in eyes with pseudoexfoliation syndrome (PXF) with or without ocular hypertension (OHTN), suggests a recent study. Factors such as older age, OHTN, higher cup-to-disc ratio (CDR), and phakia are associated with incident glaucoma.

Older age, ocular hypertension predict glaucoma in eyes with PXF syndrome

06 Aug 2026

AI-OCT for DME secondary screening cuts false-positive referrals by 45 percent

03 Aug 2026 by

An AI-based optical coherence tomography (AI-OCT) system for add-on secondary screening of diabetic macula oedema (DME) reduces false-positive DME referrals by 45 percent vs standard screening by fundus photography alone, a randomized controlled trial (RCT) in Hong Kong has shown.

AI-OCT for DME secondary screening cuts false-positive referrals by 45 percent

03 Aug 2026

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

23 Jul 2026

The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in an increased risk for ischaemic optic neuropathy (ION) at 18 months when compared with the use of sodium‒glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is), reports a study.

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

23 Jul 2026

News & Updates

Showing Ophthalmology articles

Showing

Specialty:

Tebentafusp delivers 5-year survival benefit in metastatic uveal melanoma

Tebentafusp delivers 5-year survival benefit in metastatic uveal melanoma

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

Veligrotug improves outcomes, life quality in patients with thyroid eye disease

NSAID use lowers risk of developing AMD

NSAID use lowers risk of developing AMD

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Smart eyeglasses show mixed results in feasibility study

Smart eyeglasses show mixed results in feasibility study

Dexamethasone eye drops show promise in type 1 retinopathy of prematurity

Dexamethasone eye drops show promise in type 1 retinopathy of prematurity

Prosthetic capsular bag shows potential in scleral fixation of IOL in eyes with no capsular support

Prosthetic capsular bag shows potential in scleral fixation of IOL in eyes with no capsular support

Older age, ocular hypertension predict glaucoma in eyes with PXF syndrome

Older age, ocular hypertension predict glaucoma in eyes with PXF syndrome

AI-OCT for DME secondary screening cuts false-positive referrals by 45 percent

AI-OCT for DME secondary screening cuts false-positive referrals by 45 percent

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients

GLP-1RAs up risk for ischaemic optic neuropathy in T2D patients